# MAQ-001 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06514651/  
OnCo record `nct06514651` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MAQ-001 run by MabQuest SA, now recruiting.

## Summary

MAQ-001 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06514651 by MabQuest SA, with 30 participants planned, started 2024-06-06. Conditions recorded: Advanced Solid Tumor. Interventions recorded: MAQ-001 and Ipilimumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06514651
- Phase: 1
- Setting: A Phase IA/IB Study to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of Intravenous (IV) MAQ-001 as Monotherapy and Combination Immunotherapy in Patients With Advanced Solid Tumors
- Sponsor: MabQuest SA
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06514651: https://clinicaltrials.gov/study/NCT06514651

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [MAQ-001](https://onco.cc/drugs/maq-001/)
- companies: [MabQuest](https://onco.cc/companies/mabquest/)

---
JSON: https://onco.cc/api/v1/entities/nct06514651.json